Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase
NCT00510926
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
80
Enrollment
OTHER
Sponsor class
Conditions
Myeloid Leukemia, Chronic, Chronic-Phase
Interventions
DRUG:
Imatinib Mesilate (Glivec)
Sponsor
University of Bologna